Proof of Mechanism that Investigational Therapeutic CT1812 Impacts Key Alzheimer’s Disease Biologies
Time: 10:30 am
day: Blood-Based Biomarker Focus Day
Details:
- Pharmacodynamic biomarkers of CT1812 identified
- Unbiased pathway analysis shows support that CT1812 is impacting synaptic biology, amyloid biology and neuroinflammation
- Correlates to functional or clinical outcome measures identified to support a favourable clinical impact of CT1812
- Comparative analysis shows replication across independent clinical cohorts
